RT Journal Article
T1 Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma
A1 Rodríguez-García, Alba
A1 Linares Gómez, María
A1 Morales, María Luz
A1 Allain-Maillet, Sophie
A1 Mennesson, Nicolas
A1 Sánchez, Ricardo
A1 Alonso, Rafael
A1 Leivas, Alejandra
A1 Pérez Rivilla, José Alfredo
A1 Bigot-Corbel, Edith
A1 Hermouet, Sylvie
A1 Martínez López, Joaquín
AB Multiple myeloma (MM) remains an incurable plasma cell malignancy. While its origin is enigmatic, an association with infectious pathogens including hepatitis C virus (HCV) has been suggested. Here we report nine patients with monoclonal gammopathy of undetermined significance (MGUS) or MM with previous HCV infection, six of whom received antiviral treatment. We studied the evolution of the gammopathy disease, according to anti-HCV treatment and antigen specificity of purified monoclonal immunoglobulin, determined using the INNO-LIA™ HCV Score assay, dot-blot assays, and a multiplex infectious antigen microarray. The monoclonal immunoglobulin from 6/9 patients reacted against HCV. Four of these patients received antiviral treatment and had a better evolution than untreated patients. Following antiviral treatment, one patient with MM in third relapse achieved complete remission with minimal residual disease negativity. For two patients who did not receive antiviral treatment, disease progressed. For the two patients whose monoclonal immunoglobulin did not react against HCV, antiviral treatment was not effective for MGUS or MM disease. Our results suggest a causal relationship between HCV infection and MGUS and MM progression. When HCV was eliminated, chronic antigen-stimulation disappeared, allowing control of clonal plasma cells. This opens new possibilities of treatment for MGUS and myeloma.
SN 1664-3224
YR 2022
FD 2022-01-11
LK https://hdl.handle.net/20.500.14352/101687
UL https://hdl.handle.net/20.500.14352/101687
LA eng
DS Docta Complutense
RD 13 abr 2025